SNI National is Voluntarily recalling Kratom XL 4 Pack, Maeng Da Kratom 10 Pack, Max Kratom 20 Pack, and Bali Kratom 40 pack Due to Undeclared Drug Ingredients. FDA Recalls, Market Withdrawals, & Safety Alerts, March 14, 2014. Available at: http://www.fda.gov/Safety/Recalls/ucm389350.htm.

Janchawee B, Keawpradub N, Chittrakarn S, et al. A high-performance liquid chromatographic method for determination of mitragynine in serum and its application to a pharmacokinetic study in rats. Biomed Chromatogr 2007;21(2):176-83. View abstract.

de Moraes NV, Moretti RA, Furr EB 3rd, McCurdy CR, Lanchote VL. Determination of mitragynine in rat plasma by LC-MS/MS: application to pharmacokinetics. J Chromatogr B Analyt Technol Biomed Life Sci 2009;877(24):2593-7. View abstract.

Singh D, Müller CP, Vicknasingam BK. Kratom (Mitragyna speciosa) dependence, withdrawal symptoms and craving in regular users. Drug Alcohol Depend 2014 Jun 1;139:132-7. View abstract.

Kittirattanapaiboon P, Suttajit S, Junsirimongkol B, Likhitsathian S, Srisurapanont M. Suicide risk among Thai illicit drug users with and without mental/alcohol use disorders. Neuropsychiatr Dis Treat 2014 Mar 13;10:453-8. View abstract.

Ponglux D, Wongseripipatana S, Takayama H, Kikuchi M, Kurihara M, Kitajima M, Aimi N, Sakai S. A New Indole Alkaloid, 7 alpha-Hydroxy-7H-mitragynine, from Mitragyna speciosa in Thailand. Planta Med 1994 Dec;60(6):580-1. View abstract.

Phongprueksapattana S, Putalun W, Keawpradub N, Wungsintaweekul J. Mitragyna speciosa: hairy root culture for triterpenoid production and high yield of mitragynine by regenerated plants. Z Naturforsch C 2008 Sep-Oct;63(9-10):691-8. View abstract.

Backstrom BG, Classon G, Lowenhielm P, Thelander G. [Krypton--new, deadly Internet drug. Since October 2009 have nine young persons died in Sweden]. Lakartidningen 2010;107(50):3196-3197. View abstract.

Kronstrand R, Roman M, Thelander G, Eriksson A. Unintentional fatal intoxications with mitragynine and O-desmethyltramadol from the herbal blend Krypton. J Anal Toxicol 2011;35(4):242-247. View abstract.

Roche KM, Hart K, Sangall B, Lefberg J, Bayer M. "Kratom: A Case of a Legal High". J Clin Toxicol 2008;46(7):598.

Ward J, Rosenbaum C, Hernon C, McCurdy CR, Boyer EW. Herbal medicines for the management of opioid addiction: safe and effective alternatives to conventional pharmacotherapy? CNS Drugs 2011;25(12):999-1007. View abstract.

Chan KB, Pakiam C, Rahim RA. Psychoactive plant abuse: the identification of mitragynine in ketum and in ketum preparations. Bull Narc 2005;57(1-2):249-256. View abstract.

Koch J, Mogensen J, Pedersen S, et al. Fast one-step procedure for the detection of nucleic acids in situ by primer-induced sequence-specific labeling with fluorescein-12-dUTP. Cytogenet Cell Genet 1992;60(1):1-3. View abstract.

McWhirter L, Morris S. A case report of inpatient detoxification after kratom (Mitragyna speciosa) dependence. Eur Addict Res 2010;16(4):229-231. View abstract.

Rosenbaum CD, Carreiro SP, Babu KM. Here today, gone tomorrow...and back again? A review of herbal marijuana alternatives (K2, Spice), synthetic cathinones (bath salts), kratom, Salvia divinorum, methoxetamine, and piperazines. J Med Toxicol 2012;8(1):15-32. View abstract.

Boyer EW, Babu KM, Adkins JE, McCurdy CR, Halpern JH. Self-treatment of opioid withdrawal using kratom (Mitragynia speciosa korth). Addiction 2008;103(6):1048-1050. View abstract.

Boyer EW, Babu KM, Macalino G. E. Self-treatment of opioid withdrawal with a dietary supplement, Kratom. Am J Addict 2007;16(5):352-356. View abstract.

Jansen KL, Prast CJ. Ethnopharmacology of kratom and the Mitragyna alkaloids. J Ethnopharmacol 1988;23(1):115-119.

Nelsen JL, Lapoint J, Hodgman MJ, Aldous KM. Seizure and coma following Kratom (Mitragynina speciosa Korth) exposure. J Med Toxicol 2010;6(4):424-426. View abstract.

Sheleg SV, Collins GB. A coincidence of addiction to "Kratom" and severe primary hypothyroidism. J Addict Med 2011;5(4):300-301. View abstract.

Kapp FG, Maurer HH, Auwarter V, Winkelmann M, Hermanns-Clausen M. Intrahepatic cholestasis following abuse of powdered kratom (Mitragyna speciosa). J Med Toxicol 2011;7(3):227-231. View abstract.

Kong WM, Chik Z, Ramachandra M, et al. Evaluation of the effects of Mitragyna speciosa alkaloid extract on cytochrome P450 enzymes using a high throughput assay. Molecules. 2011;16(9):7344-7356. View abstract.

Arndt T, Claussen U, Gussregen B, et al. Kratom alkaloids and O-desmethyltramadol in urine of a "Krypton" herbal mixture consumer. Forensic Sci Int 2011;208(1-3):47-52. View abstract.

US Food and Drug Administration (2014). SNI National is Voluntarily recalling Kratom XL 4 Pack, Maeng Da Kratom 10 Pack, Max Kratom 20 Pack, and Bali Kratom 40 pack Due to Undeclared Drug Ingredients [Press Release].

Philipp AA, Wissenbach DK, Weber AA, Zapp J, Maurer HH. Metabolism studies of the Kratom alkaloids mitraciliatine and isopaynantheine, diastereomers of the main alkaloids mitragynine and paynantheine, in rat and human urine using liquid chromatography-linear ion trap-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2011;879(15-16):1049-1055. View abstract.

Philipp AA, Meyer MR, Wissenbach DK, et al. Monitoring of kratom or Krypton intake in urine using GC-MS in clinical and forensic toxicology. Anal Bioanal Chem 2011;400(1):127-135. View abstract.

Philipp AA, Wissenbach DK, Weber AA, Zapp J, Maurer HH. Metabolism studies of the Kratom alkaloid speciociliatine, a diastereomer of the main alkaloid mitragynine, in rat and human urine using liquid chromatography-linear ion trap mass spectrometry. Anal Bioanal Chem 2011;399(8):2747-2753. View abstract.

Philipp AA, Wissenbach DK, Weber AA, Zapp J, Maurer HH. Phase I and II metabolites of speciogynine, a diastereomer of the main Kratom alkaloid mitragynine, identified in rat and human urine by liquid chromatography coupled to low- and high-resolution linear ion trap mass spectrometry. J Mass Spectrom 2010;45(11):1344-1357. View abstract.

Philipp AA, Wissenbach DK, Weber AA, et al. Use of liquid chromatography coupled to low- and high-resolution linear ion trap mass spectrometry for studying the metabolism of paynantheine, an alkaloid of the herbal drug Kratom in rat and human urine. Anal Bioanal Chem 2010;396(7):2379-2391. View abstract.

Babu KM, McCurdy CR, Boyer EW. Opioid receptors and legal highs: Salvia divinorum and Kratom. Clin Toxicol (Phila) 2008;46(2):146-152. View abstract.

Parthasarathy S, Ramanathan S, Ismail S, et al. Determination of mitragynine in plasma with solid-phase extraction and rapid HPLC-UV analysis, and its application to a pharmacokinetic study in rat. Anal Bioanal Chem 2010;397(5):2023-2030. View abstract.

Philipp AA, Wissenbach DK, Zoerntlein SW, et al. Studies on the metabolism of mitragynine, the main alkaloid of the herbal drug Kratom, in rat and human urine using liquid chromatography-linear ion trap mass spectrometry. J Mass Spectrom 2009;44(8):1249-1261. View abstract.

Drug Enforcement Administration. Kratom (Mytragyna speciosa korth). Available at: http://www.deadiversion.usdoj.gov/drug_chem_info/kratom.pdf.

Ancuceanu RV, Dinu M, Anghel AI, et al. Recent prohibition of certain psychoactive ethnobotanicals in Romania. Farmacia 2010;58(2):-121-127.

Statement from FDA Commissioner Scott Gottlieb, M.D. on FDA advisory about deadly risks associated with kratom. FDA Statement: Press Announcements, November 14, 2017. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm584970.htm. Accessed: November 14, 2017.

Castillo A, Payne JD, Nugent K. Posterior reversible leukoencephalopathy syndrome after kratom ingestion. Proc (Bayl Univ Med Cent). 2017;30(3):355-357. View abstract.

Cumpston KL, Carter M, Wills BK. Clinical outcomes after Kratom exposures: A poison center case series. Am J Emerg Med. 2018;36(1):166-168. View abstract.

Griffin OH, Webb ME. The Scheduling of Kratom and Selective Use of Data. J Psychoactive Drugs. 2017 Sep 22:1-7. doi: 10.1080/02791072.2017.1371363. View abstract.

Guddat S, Görgens C, Steinhart V, Schänzer W, Thevis M. Mitragynine (Kratom) - monitoring in sports drug testing. Drug Test Anal. 2016;8(11-12):1114-1118. View abstract.

Lydecker AG, Sharma A, McCurdy CR, Avery BA, Babu KM, Boyer EW. Suspected Adulteration of Commercial Kratom Products with 7-Hydroxymitragynine. J Med Toxicol. 2016;12(4):341-349. View abstract.

White CM. Pharmacologic and clinical assessment of kratom. Am J Health Syst Pharm. 2017. pii: ajhp161035. View abstract.

Statement from FDA Commissioner Scott Gottlieb, M.D., on the agency's scientific evidence on the presence of opioid compounds in kratom, underscoring its potential for abuse. FDA Statement. February 6, 2018. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm595622.htm. Accessed 4/18/2018.

FDA Adverse Event Reporting System: Kratom Deaths. February 6, 2018. https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/CDERFOIAElectronicReadingRoom/UCM595575.pdf. Accessed March 6, 2018.

Multistate Outbreak of Salmonella Infections Linked to Kratom. Centers for Disease Control and Prevention: 2018 Outbreaks. March 15, 2018. https://www.cdc.gov/salmonella/kratom-02-18/index.html. Accessed March 16, 2018

Trakulsrichai S, Sathirakul K, Auparakkitanon S, et al. Pharmacokinetics of mitragynine in man. Drug Des Devel Ther. 2015;9:2421-9. View abstract.

Kruegel AC, Grundmann O. The medicinal chemistry and neuropharmacology of kratom: A preliminary discussion of a promising medicinal plant and analysis of its potential for abuse.Neuropharmacology. 2017. pii: S0028-3908(17)30393-3. View abstract.

Singh D, Murugaiyah V, Hamid SBS, et al. Assessment of gonadotropins and testosterone hormone levels in regular Mitragyna speciosa (Korth.) users. J Ethnopharmacol 2018;221:30-6. doi: 10.1016/j.jep.2018.04.005. View abstract.

Singh D, Müller CP, Murugaiyah V, et al. Evaluating the hematological and clinical-chemistry parameters of kratom (Mitragyna speciosa) users in Malaysia. J Ethnopharmacol 2018;214:197-206. doi: 10.1016/j.jep.2017.12.017. View abstract.

Olsen EO, O'Donnell J, Mattson CL, Schier JG, Wilson N. Notes from the field: Unintentional drug overdose deaths with kratom detected - 27 States, July 2016-December 2017. MMWR Morb Mortal Wkly Rep. 2019;68(14):326-327. View abstract.

Hughes RL. Fatal combination of mitragynine and quetiapine - a case report with discussion of a potential herb-drug interaction. Forensic Sci Med Pathol. 2019 Mar;15(1):110-113. View abstract.

Gershman K, Timm K, Frank M, et al. Deaths in Colorado Attributed to Kratom. N Engl J Med. 2019 Jan 3;380(1):97-98. View abstract.

Mackay L, Abrahams R. Novel case of maternal and neonatal kratom dependence and withdrawal. Can Fam Physician. 2018 Feb;64(2):121-122. View abstract.

Davidson L, Rawat M, Stojanovski S, Chandrasekharan P. Natural drugs, not so natural effects: Neonatal abstinence syndrome secondary to 'kratom'. J Neonatal Perinatal Med. 2019;12(1):109-112. View abstract.

Smid MC, Charles JE, Gordon AJ, Wright TE. Use of Kratom, an Opioid-like Traditional Herb, in Pregnancy. Obstet Gynecol. 2018 Oct;132(4):926-928. View abstract.

Muhammad BY, Abdullahi AD, Kadir, SS, Abdul Razak TB, Ahmed QU. In-utero effects of the crude ethanolic extract of the leaves of Mitragyna speciose on neural tube formation in rats. Asian J Exp Biol Sci. 2010;1(2):404-408.

Aldyab M, Ells PF, Bui R, Chapman TD, Lee H. Kratom-Induced Cholestatic Liver Injury Mimicking Anti-Mitochondrial Antibody-Negative Primary Biliary Cholangitis: A Case Report and Review of Literature. Gastroenterology Res. 2019 Aug;12(4):211-215. View abstract.

Hemby SE, McIntosh S, Leon F, Cutler SJ, McCurdy CR. Abuse liability and therapeutic potential of the Mitragyna speciosa (kratom) alkaloids mitragynine and 7-hydroxymitragynine. Addict Biol. 2019 Sep;24(5):874-885. View abstract.

Nacca N, Schult RF, Li L, Spink DC, Ginsberg G, Navarette K, Marraffa J. Kratom Adulterated with Phenylethylamine and Associated Intracerebral Hemorrhage: Linking Toxicologists and Public Health Officials to Identify Dangerous Adulterants. J Med Toxicol. 2019 Nov 11. View abstract.

Abdullah HMA, Haq I, Lamfers R. Cardiac arrest in a young healthy male patient secondary to kratom ingestion: is this 'legal high' substance more dangerous than initially thought ? BMJ Case Rep. 2019 Jul 19;12(7). pii: e229778. View abstract.

Eggleston W, Stoppacher R, Suen K, Marraffa JM, Nelson LS. Kratom Use and Toxicities in the United States. Pharmacotherapy. 2019 Jul;39(7):775-777. doi: 10.1002/phar.2280. Epub 2019 Jun 13. View abstract.

Afzal H, Esang M, Rahman S. A case of kratom-induced seizures. Cureus. 2020;12(1):e6588. View abstract.

ELJack A, Beasley M, Ibrahim H, Taha M, Werns S. Kratom-associated ventricular fibrillation. Am J Ther. 2020. Online ahead of print. View abstract.

Schimmel J, Dart RC. Kratom (Mitragyna speciosa) liver injury: a comprehensive review. Drugs. 2020;80(3):263-83. View abstract.

Matson M, Schenk N. Fatality of 33-year-old man involving kratom toxicity. J Forensic Sci. 2019;64(6):1933-5. View abstract.

Vijeepallam K, Pandy V, Murugan DD, Naidu M. Methanolic extract of Mitragyna speciosa Korth leaf inhibits ethanol seeking behaviour in mice: involvement of antidopaminergic mechanism. Metab Brain Dis. 2019;34(6):1713-22. View abstract.

Obeng S, Kamble SH, Reeves ME, et al. Investigation of the adrenergic and opioid binding affinities, metabolic stability, plasma protein binding properties, and functional effects of selected indole-based kratom alkaloids. J Med Chem. 2020;63(1):433-9. View abstract.

Hassan R, Pike See C, Sreenivasan S, Mansor SM, Müller CP, Hassan Z. Mitragynine attenuates morphine withdrawal effects in rats - a comparison with methadone and buprenorphine. Front Psychiatry. 2020;11:411. View abstract.

Vicknasingam B, Chooi WT, Rahim AA, et al. Kratom and pain tolerance: A randomized, placebo-controlled, double-blind study. Yale J Biol Med. 2020;93(2):229-238. View abstract.

Ahmad J, Odin JA, Hayashi PH, et al. Liver injury associated with kratom, a popular opioid-like product: Experience from the U.S. drug induced liver injury network and a review of the literature. Drug Alcohol Depend. 2021;218:108426. View abstract.

Prozialeck WC, Edwards JR, Lamar PC, et al. Evaluation of the mitragynine content, levels of toxic metals and the presence of microbes in kratom products purchased in the western suburbs of Chicago. Int J Environ Res Public Health. 2020;17(15):5512. View abstract.

Leong Abdullah MFI, Tan KL, Narayanan S, et al. Is kratom (Mitragyna speciosa Korth.) use associated with ECG abnormalities? Electrocardiogram comparisons between regular kratom users and controls. Clin Toxicol (Phila). 2020:1-9. View abstract.

Davidson C, Cao D, King T, et al. A comparative analysis of kratom exposure cases in Thailand and the United States from 2010-2017. Am J Drug Alcohol Abuse. 2020:1-10. View abstract.

Graves JM, Dilley JA, Terpak L, et al. Kratom exposures among older adults reported to U.S. poison centers, 2014-2019. J Am Geriatr Soc 2021;69(8):2176-2184. View abstract.

Leong Bin Abdullah MFI, Singh D. Assessment of Cardiovascular Functioning Among Regular Kratom (Mitragyna speciosa Korth) Users: A Case Series. Front Pharmacol 2021;12:723567. View abstract.

Lei J, Butz A, Valentino N. Management of kratom dependence with buprenorphine/naloxone in a veteran population. Subst Abus 2021;42(4):497-502. View abstract.

Burke DJ, Mahonski SG, Van Cott AC. Breakthrough Seizure Associated With Kratom Use in Patients With Epilepsy. Neurol Clin Pract 2021;11(1):78-84. View abstract.

Regan GA, Papadakos PJ. Intracerebral hemorrhage after kratom ingestion. JAAPA 2021;34(4):33-36. View abstract.

Halim SA, Low JH, Chee YC, Alias MR. Seizures among young adults consuming kratom beverages in Malaysia: A case series. Epilepsy Behav 2021;121(Pt A):108057. View abstract.

Jensen AN, Truong QN, Jameson M, Nadal CN. Kratom-induced transaminitis with subsequent precipitated opioid withdrawal following naltrexone. Ment Health Clin 2021;11(3):220-224. View abstract.

Torres-Ortiz A, Al Zein S, Alqudsi M. A Case of Hyperkalemia Induced by Kratom (Mitragyna speciosa). Cureus 2022;14(4):e24036. View abstract.

Sangani V, Sunnoqrot N, Gargis K, Ranabhotu A, Mubasher A, Pokal M. Unusual Presentation of Kratom Overdose With Rhabdomyolysis, Transient Hearing Loss, and Heart Failure. J Investig Med High Impact Case Rep 2021;9:23247096211005069. View abstract.

Botejue M, Walia G, Shahin O, Sharma J, Zackria R. Kratom-Induced Liver Injury: A Case Series and Clinical Implications. Cureus 2021;13(4):e14679. View abstract.

Patel P, Aknouk M, Keating S, et al. Cheating Death: A Rare Case Presentation of Kratom Toxicity. Cureus 2021;13(7):e16582. View abstract.

Brogdon HD, McPhee MM, Paine MF, Cox EJ, Burns AG. A Case of Potential Pharmacokinetic Kratom-drug Interactions Resulting in Toxicity and Subsequent Treatment of Kratom Use Disorder With Buprenorphine/Naloxone. J Addict Med 2022. View abstract.

Matos-Casano HA, Nanduri S. Transient Paralysis: A Novel Expression of Kratom Toxicity in Humans. Neurol Clin Pract 2021;11(1):e28-e29. View abstract.

Basheer M, Hassan Z, Gam LH. Upregulation of Brain's Calcium Binding Proteins in Mitragynine Dependence: A Potential Cellular Mechanism to Addiction. Int J Med Sci 2023;20(1):102-113. View abstract.

Chinnappan J, Navari Y, Casini D, Palanisamy N, Parikh N, Seedahmed E. Kratom-Induced Acute Respiratory Distress Syndrome (ARDS). Eur J Case Rep Intern Med 2023;10(4):003835. View abstract.

Deebel NA, Scarberry K, O'Connor CA, et al. Investigating the Impact of Kratom (Mitragyna speciosa) Use Upon Male Sexual Health. Res Rep Urol 2023;15:69-76. View abstract.

Eudaley ST, Brooks SP, Hamilton LA. Case Report: Possible Serotonin Syndrome in a Patient Taking Kratom and Multiple Serotonergic Agents. J Pharm Pract 2022. View abstract.

Helander A, Rylski A. Drug testing for mitragynine and kratom: Analytical challenges and medico-legal considerations. Drug Test Anal 2023;15(2):213-219. View abstract.

Hong S, Zimmerman PE, Rao V, Markwalter DW. Buprenorphine-Naloxone in the Setting of Kratom Withdrawal, Opioid Use Disorder, and Stage IV Lung Adenocarcinoma. J Palliat Med 2023;26(5):734-736. View abstract.

Hughs M, Kish-Trier E, O'Brien A, McMillin GA. Analysis of Mitragynine and Speciociliatine in Umbilical Cord by LC-MS-MS for Detecting Prenatal Exposure to Kratom. J Anal Toxicol 2023;46(9):957-964. View abstract.

Jasim RK, Singh D, Gam LH. Development and validation of ELISA for screening of Kratom (Mitragyna speciosa) habitual users using urinary AZ122 biomarker. Biotechnol Appl Biochem 2023;70(2):707-715. View abstract.

Johnson KM, Lause M, Chung C, Massick S. Kratom ingestion associated with photodistributed hyperpigmentation. Int J Dermatol 2023. View abstract.

Kamble SH, Obeng S, León F, et al. Pharmacokinetic and Pharmacodynamic Consequences of Cytochrome P450 3A Inhibition on Mitragynine Metabolism in Rats. J Pharmacol Exp Ther 2023;385(3):180-192. View abstract.

LeSaint KT, Yin S, Sharma A, Avery BA, McCurdy CR, Waksman JC. Acute Renal Insufficiency Associated With Consumption of Hydrocodone- and Morphine-Adulterated Kratom (Mitragyna Speciosa). J Emerg Med 2022;63(1):e28-e30. View abstract.

Martin G, Collins DP, Valenzuela H. Life-Threatening Hyponatremia Secondary to Chronic Kratom Use: A Case Presentation. Cureus 2022;14(9):e29073. View abstract.

Mata DC, Chang HH. Postmortem Mitragynine Distribution in a Single Drug Fatality Case. Acad Forensic Pathol 2023;13(1):34-40. View abstract.

Obeng S, Leon F, Patel A, et al. Interactive Effects of µ-Opioid and Adrenergic-a (2) Receptor Agonists in Rats: Pharmacological Investigation of the Primary Kratom Alkaloid Mitragynine and Its Metabolite 7-Hydroxymitragynine. J Pharmacol Exp Ther 2022;383(3):182-198. View abstract.

Peran D, Stern M, Cernohorsky P, Sykora R, Popela S, Duska F. Mitragyna speciosa (Kratom) poisoning: Findings from ten cases. Toxicon 2023;225:107054. View abstract.

Powell LR, Ryser TJ, Morey GE, Cole R. Kratom as a novel cause of photodistributed hyperpigmentation. JAAD Case Rep 2022;28:145-148. View abstract.

Prozialeck W, Fowler A, Edwards J. Public Health Implications and Possible Sources of Lead (Pb) as a Contaminant of Poorly Regulated Kratom Products in the United States. Toxics 2022;10(7):398. View abstract.

Reich N, Salvo G, Leong D, Wan V, Kosatsky T. Kratom exposures managed by the British Columbia poison centre, 2012-2019: a descriptive analysis. CMAJ Open 2022;10(3):E755-E761. View abstract.

Roma K, Mohammed S, Sieck B, Naik K, Wahid S. Kratom-induced acute liver injury: A case study and the importance of herbal supplement regulation. J Hepatol 2023. View abstract.

Schwensohn C, Nsubuga J, Cronquist L, et al. A Multiple-Serotype Outbreak of Salmonella Infections Linked to Kratom, United States, 2017-2018. Foodborne Pathog Dis 2022;19(9):648-653. View abstract.

Settle AG, Yang C. A Case of Severe Kratom Addiction Contributing to a Suicide Attempt. Cureus 2022;14(9):e29698. View abstract.

Smith KE, Feldman JD, Dunn KE, et al. Examining the paradoxical effects of kratom: a narrative inquiry. Front Pharmacol 2023;14:1174139. View abstract.

Suhaimi FW, Zul Aznal AN, Mohamad Nor Hazalin NA, Teh LK, Hassan Z, Salleh MZ. Kratom (M. speciosa) exposure during adolescence caused long-lasting cognitive behavioural deficits associated with perturbated brain metabolism pathways in adult rats. Behav Brain Res 2023;446:114411. View abstract.

Tanna RS, Nguyen JT, Hadi DL, et al. Clinical Assessment of the Drug Interaction Potential of the Psychotropic Natural Product Kratom. Clin Pharmacol Ther 2023;113(6):1315-1325. View abstract.

Thewjitcharoen Y, Krittiyawong S, Nakasatien S, Himathongkam T. Kratom-Associated Mixed Cholestatic-Hepatocellular Liver Injury in a Patient With Long COVID: A case Report. Clin Med Insights Case Rep 2022;15:11795476221132824. View abstract.

Vanani NB, Stevanovic SG, Stevanovic N. Adverse Drug Interaction Between Kratom and Amitriptyline With Gastrointestinal and Mild Hepatic Effects. Cureus 2023;15(1):e33809. View abstract.

Zhang P, Wei W, Zhang X, Wen C, Ovatlarnporn C, Olatunji OJ. Antidiabetic and antioxidant activities of Mitragyna speciosa (kratom) leaf extract in type 2 diabetic rats. Biomed Pharmacother 2023;162:114689. View abstract.

Zul Aznal AN, Mohamad Nor Hazalin NA, Hassan Z, et al. Adolescent kratom exposure affects cognitive behaviours and brain metabolite profiles in Sprague-Dawley rats. Front Pharmacol 2022;13:1057423. View abstract.

Dasgupta A, Ye Z. Severe jaundice with life-threatening liver failure after Kratom use: Reversed by plasma exchange. Transfus Apher Sci 2024. View abstract.

Krantz MJ, Rudo TJ, Haigney MCP, et al. Ventricular Arrhythmias Associated With Over-the-Counter and Recreational Opioids. J Am Coll Cardiol 2023;81(23):2258-2268. View abstract.

Shi T, Shea JL. A case of fatal overdose involving both hydromorphone and kratom. J Forensic Sci 2024;69(1):355-358. View abstract.

Torrico T, Patel K, Nikolov N, Salam MT, Padhy R, Weinstein D. Presence of kratom in opioid overdose deaths: findings from coroner postmortem toxicological report. Front Psychiatry 2024;14:1332999. View abstract.

Jarka C, Gregoire K. Precipitated withdrawal with kratom use following naltrexone administration. Ment Health Clin 2023;13(3):155-158. View abstract.

Ahmed S, Tran QV, McLean M. The Great Imitator: A Case of Accidental Kratom Overdose. Cureus 2023;15(8):e43144. View abstract.